Clinical Trial Update: Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma [Phase 3]

View source ↗

Summary

A Phase 3 trial is planned to compare QL2302 with Tezspire in patients with severe asthma. Recruitment has not yet begun.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• QL2302
• Tezspire (tezepelumab)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Asthma | Phase 3 | Status: NOT_YET_RECRUITING